arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Neuronetics, Inc.

STIM
$2.45 ▼ -0.25 (-9.43%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
40 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuronetics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $179.2M
Dividend Yield —
Revenue Growth 9.1% ↗
Op. Margin -3.6% ↗
ROIC -1.5% ↗
FCF / Share $-0.01 ↗
Trailing P/E —
Price / Book 10.5x
FCF Yield —
Debt / Equity 3.45
info Valuation on last close. End-of-day price, Nov 5, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.57M
↑ +9.1% —
Net Income Profit after all expenses
$-3.44M
↑ +66.0% —
Operating Margin Operating profit as % of sales
-3.6%
↑ +86.2% 10th
FCF / Share Free cash flow per share
$-0.01
↑ +89.8% —
Long-Term Debt Long-term obligations
$61.52M
— +0.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
10
Returns ↓
4
Financial Health ↑
23
Cash Quality ↓
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 40 quarters